RxDoctor Payments Data

Katey Waldon, NP

Family · Fayetteville, NYNPI 1487017901

Payments from drug & device makers

$4,763in general payments, 2019–2025

Across 256 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$547
  • Sanofi$442
  • Regeneron Healthcare Solutions, Inc.$428
  • Sun Pharmaceutical Industries Inc.$387
  • UCB, Inc.$262
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,62097%
  • Education$1433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,763 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$76,674
Medicare patients
380
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$83,090
Dupixent PenDupilumab12$44,905
Ketoconazole183$3,106
Clobetasol Propionate88$3,092
Metronidazole47$2,848
Triamcinolone Acetonide100$1,346
Tacrolimus11$1,269
Doxycycline Hyclate34$748
Clindamycin Phosphate21$674
Fluconazole37$594
Imiquimod17$485
Fluticasone Propionate19$471
Mupirocin81$456
Ciclopirox16$384
CiclopiroxCiclopirox Olamine11$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$89$83,09017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Fayetteville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →